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Abstract
Background: This study clinically evaluated the effect of botulinum toxin type A (BTX-A) in the temporomandibular
disorder (TMD) treatment using Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD).
Methods: A total of 21 TMD patients were recruited to be treated with BTX-A injections on the bilateral masseter
and temporalis muscles and were followed up by an oral and maxillofacial surgeon highly experienced in the TMD
treatment. For each patient, diagnostic data gathering were conducted according to the RDC/TMD. Characteristic
pain intensity, disability points, chronic pain grade, depression index, and grade of nonspecific physical symptoms
were evaluated. Wilcoxon signed-rank test was applied for statistical analysis.
Results: The results showed that more than half of the participants (85.7 %) had parafunctional oral habits such as
bruxism or clenching. In comparison between pre- and post-treatment results, graded pain score, characteristic pain
intensity, disability points, chronic pain grade, and grade of nonspecific physical symptoms showed statistically
significant differences after the BTX-A injection therapy (p < 0.05). Most patients experienced collective decrease in
clinical manifestations of TMD including pain relief and improved masticatory functions after the treatment.
Conclusions: Within the limitation of our study, BTX-A injections in masticatory musculatures of TMD patients
could be considered as a useful option for controlling complex TMD and helping its associated symptoms.
Keywords: Botulinum toxin type A, Temporomandibular disorder, Research diagnostic criteria for
temporomandibular disorder
Background
Temporomandibular disorders (TMD), musculoskeletal
disorders of the masticatory system, are common clinical
labels for pain in the orofacial area. Causes of TMD symp-
toms are often complex and idiopathic, and problems
involve extra-articular and intra-articular pathologic condi-
tions or a combination of the both. TMD patients manifest
various symptoms including myofascial tenderness and
pain, headache, joint noises, trismus, and even tinnitus. In
symptomatic muscle areas, a number of trigger points
could be present, and palpating these musculatures gener-
ally initiates radiating discomforts along with cascading
pains on multiple muscle and neuronal tracks. Depending
on contributing factors, these symptoms may be transient
or perpetuating [1].
Successful TMD treatment starts from correctly differ-
entiating the origin of symptoms. Since myofascial pains
and mouth opening limitation are the most frequent
symptoms in masticatory muscle disorders, directing
treatments at the muscular components of TMD could
yield therapeutic gains. Therefore, noninvasive conserva-
tive treatments such as counseling, soft diet, behavior
medicine, physiotherapy, oral appliances, pharmacother-
apy, and botulinum toxin injections are reported to be
effective as first-line therapies for extra-articular patho-
logic conditions [2].
Intra-articular pathologic conditions such as internal
derangement and osteoarthritis could also benefit from the
reversible interventions used to treat myofascial pains.
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Acute patients, however, may require intra-articular injec-
tion of lidocaine, hyaluronic acid, or even corticosteroid [3].
When the symptoms and pains surpass the effectiveness of
these techniques, surgical approaches such as arthrocent-
esis, arthroscopy, and TMJ open surgeries such as arthro-
plasty may be performed to treat anatomical pathology.
The purpose of this study was to clinically evaluate the
effect of botulinum toxin injection in treating TMD arising
from both intra-articular and extra-articular pathologies
based on Research Diagnostic Criteria for Temporoman-




A total of 21 TMD patients (17 females, 4 males; 4.25:1)
were recruited from Feb. 2007 to Sept. 2013 to be treated
with botulinum toxin type A (BTX-A) injection. The
participants had chief complaints of myofascial pain, tris-
mus, and/or TMJ sounds. The mean age of patients was
37.0 ± 15.1 years (ranged from 15.2 to 69.0 years). A de-
tailed sex and age distribution is shown in Table 1.
The subjects filled out the Korean-translated version of
RDC/TMD Axis II questionnaires before and after the
end of the treatment [4]. The patients who did not
complete the questionnaires were removed from the study
group. The medical charts were reviewed by a trained oral
and maxillofacial surgeon along with the clinical record,
radiographic examination, and bone scan. RDC/TMD
Axis I criteria were used to diagnose the TMDs, and they
were further classified under the TMD subtypes proposed
by the Japanese Society for the Temporomandibular Joint
(JSTMJ) in 2001: type I, masticatory muscle disorder; type
II, capsule-ligament disorder; type III, disc disorder; type
IV, degenerative joint diseases, osteoarthritis, and osteoar-
throsis; and type V, cases not included in types I–IV [5].
The main diagnosis category was selected when multiple
diagnoses were given. Inclusion criteria were as follows:
(1) patients who received BTX-A injection therapy during
the study period, (2) patients with complete medical
records, and (3) patients with TMD/RDC follow-ups.
Before the BTX-A treatment, all patients had undergone
noninvasive conservative therapies including counseling,
pharmacotherapy, behavior medicine, and physical therap-
ies. As for first-line pharmacotherapy, various medications
such as NSAIDs, corticosteroids, analgesics, tricyclic anti-
depressants, and muscle relaxant were prescribed depend-
ing on the pathologic conditions of the patients. Physical
therapies were performed in forms of low-level laser ther-
apy (LLLT), ethyl chloride spray and stretch technique,
jaw stretching exercise, and stabilization splints.
This research was approved by the Institutional Review
Boards of the SNUBH (IRB #: B-1305-204-110), and in-
formed consent was obtained from all participants prior
to initiating the study.
BTX-A injection technique
BTX-A powders (Dysport®, Ipsen Ltd, Slough, UK) were
kept frozen in sterile vials until each use. Preparation of
the BTX-A solution was done under the manufacturer’s
guidelines. The solution was prepared by adding 0.9 %
normal saline without a preservative to the powders
until 2 ml of final dilution. Injection sites were wiped
with 70 % ethanol swab, and dry sterile gauze for skin
preparation and aspirations were performed before each
injection. Calibrated 1.0-ml tuberculin syringes with 26
gauge needles were used for the injection. The prepared
solution was used within an hour for its maximum
potency.
The patients received a total of 500 U of Dysport (BTX-
A) injections into the bilateral masseter and temporalis
muscles with the injection ratio of 3 to 2, respectively.
Before injections, patients were asked to clench their jaws
to make the injection sites more prominent. Using mul-
tiple injection technique, each masseter and temporalis
muscle had three injection sites, with diffusion of approxi-
mately 1 cm apart from each sites. The treated patients
were followed up by a dentist highly experienced in the
TMD treatment.
RDC/TMD Axis II assessment
Each subject filled out the RDC/TMD Axis II question-
naire before and after the end of the treatment. Unfinished
questionnaires were excluded from the study. Among the
RDC/TMD, characteristic pain intensity, disability points,
chronic pain grade, depression index, and grade of non-
specific physical symptoms were analyzed [6].
1) Characteristic pain intensity (CPI)
The characteristic pain intensity was measured
by taking the mean of Q7, Q8, and Q9 and
multiplied by 10. The Q7, Q8, and Q9 scores
were under the GCP scale.
Table 1 Sex and age distribution
Age Sex Total
Male Female
15 to 19 1 2 3
20 to 29 3 3
30 to 39 3 5 8
40 to 49 3 3
50 to 59 2 2
Over 60 2 2
Total 4 17 21
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2) Disability points (DP)
The disability points were gained by adding points
for disability days and disability score. The
disability days were obtained by the answer to
Q10, and appropriate disability points (0 to 3)
were assigned to range of days. For the disability
score, the mean value of Q11, Q12, and Q13 was
multiplied by 10. Appropriate disability points (0
to 3) were assigned to range of scores. All
obtained scores were under the GCP scale.
3) Chronic pain grade (CPG)
The chronic pain grade classification was termed
as following and using previously calculated CPI
and DP (Table 2).
4) Depression index (DI)
The mean of the numeric values (scored 0 to 4) to
RDC/TMD Axis II Q20 (items: b, e, h, i, k, l, m, n,
v, y, cc, dd, ee, f, g, q, z, aa, bb, ff ) showed the
degree of psychological pain.
5) Nonspecific physical symptoms (pain items
included)
The mean of the numeric values (scored 0 to 4) to
RDC/TMD Axis II Q20 related to the pain (items:
a, c, d, j, o, p, r, s, t, u, w, x) indicated the degree
of atypical somatization and physical pain.
6) Nonspecific physical symptoms (pain items
excluded)
The mean of the numeric values (scored 0 to 4)
on RDC/TMD Axis II Q20 (items: c, r, s, t, u, w,
x) showed the nonspecific physical symptoms,
pain items excluded.
Statistical analyses
Statistical analysis was accomplished using Wilcoxon
signed-rank test (SPSS Inc., ver. 19.0, USA) to evaluate the
effectiveness of the BTX-A treatment in the subjects on
pain intensity, disability days, graded chronic pain scale,
depression, nonspecific physical symptoms, and jaw dis-
ability. Statistical significance was defined as p < 0.05.
Results
More than half of the participants (85.7 %) had parafunc-
tional oral habits such as bruxism, clenching, and unilateral
mastication. TMD subtypes of the patients were catego-
rized as following according to the JSTMJ classifications
(2001) [5]: type I (n = 4), type II (n = 0), type III (n = 5), type
IV (n = 8), and type V (n = 4). The patients were followed
up for 2.9 ± 2.0 years by a dentist highly experienced in the
TMD treatment.
Overall, intramuscular injections of BTX-A into the
masseter and temporalis muscles decreased tenderness
and pain. In comparison between pre- and post-treatment
results, graded pain score, characteristic pain intensity,
disability points, chronic pain grade, and grade of nonspe-
cific physical symptoms showed statistically significant
differences after the BTX-A injection therapy (p < 0.05).
Depression index, however, did not show significant
changes (Table 3). Changes in graded pain score (GPS)
among the different TMD subtype groups show that
disability levels of most patients shifted towards lower
degrees of disability after the BTX-A treatments. It also
suggests that even after most TMD symptoms subside,
some disabilities still remain (Table 4).
Discussion
The RDC/TMD is broadly accepted among several diag-
nostic systems that had been proposed to classify often
complex and idiopathic TMDs. Developed by Dworkin and
LeResche in 1992, this diagnostic system has been used to
classify TMD patients with dual-axis assessments: a clinical
and radiographic diagnosis based on pathophysiology (Axis
I) and evaluation of psychological status and pain-related
disability (Axis II) [6]. With its standardization of diagnostic
criteria, this system has been validated for both research
and clinical use [7].
The botulinum toxin is known to have seven serotypes
(labeled A to G) produced by different Clostridium botu-
linum strains, and serotype A is particularly important and
the only commercially available form used in clinics for its
biologic activity. The botulinum toxin serotype A (BTX-A),
a naturally occurring neurotoxic protein, decreases the
muscle contractions by selectively impairing the exocytosis
of acetylcholine (ACH) at the neuromuscular junction of
Table 2 Graded pain score analysis
Degree Group Pre-treatment (n)
No disability Grade 0 Absence of TMD and pain prior 6 months
Low disability Grade I Low intensity; CPI < 50, DP < 3
Grade II High intensity; CPI≥ 50, DP < 3
High disability Grade III Moderately limiting; DP 3–4 (CPI unrelated)
Grade IV Severely limiting; DP 5–6 (CPI unrelated)




valueMean S.D. Mean S.D.
VAS 31.95 13.39 25.71 8.29 0.004*
CPI 55.24 23.86 45.40 15.54 0.017*
DP 3.48 2.11 2.62 1.53 0.011*
CPG 2.90 1.18 2.38 1.02 0.026*
DI 1.15 0.84 1.15 0.88 0.59
NSPI 1.29 0.92 1.11 0.83 0.008*
NSPE 1.07 0.95 0.98 0.90 0.026*
VAS Visual Analog Scale, CPI characteristic pain intensity, DP disability points,
CPG chronic pain grade, DI depression index, NSPI nonspecific physical
symptoms (pain items included), NSPE nonspecific physical symptoms (pain
items excluded)
*Statistically significant (p < 0.05)
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presynaptic motor nerve ending. Upon injection, this
neurotoxin can effectively reduce the local muscle intensity
that can last up to 3 to 6 months before forming a new
muscular reinnervation and return to its full function, with-
out significant side effects[8]. BTX-A has been used in
treating a variety of medical conditions associated with
muscle contraction or pain. In treating orofacial pains,
botulinum toxin is usually injected to a number of facial
and masticatory muscles including the masseter, temporalis,
and other muscles that may associate with TMD.
A growing number of dentists are caring their patients
with this neurotoxin for esthetic and therapeutic treat-
ments in oral and maxillofacial areas. According to a
survey, 16 % of North American dentists are estimated
to use BTX-A in their practices [9]. After introduction
of commercial brands of BTX-A such as Botox and
Dysport, its injection therapy on orofacial muscles be-
came a valuable adjunct in managing the myofascial
components of TMD. Supporting literature dates back
three decades, with its successes reported in the various
therapeutic applications since the 1980s [10].
BTX-A has been used to treat a wide spectrum of med-
ical conditions such as muscular spasm, hypertrophy, and
various cosmetic corrections, and its applications are still
expanding. In one report, injection of BTX-A into the lat-
eral pterygoid muscles was recommended as the treatment
choice for elderly patients with systemic/neurological dis-
eases who experienced habitual dislocation of the TMJ [11].
BTX-A injections are also known to be useful in treating
chronic neuropathic pain, possibly with its analgesic effect
that is suggested to employ independent action on periph-
eral nociceptors by regulating release of various endogen-
ous chemicals such as glutamate, calcitonin gene-related
peptide, and substance P [12].
Traumatized TMJ could naturally self-heal or use ad-
aptational mechanism without serious complications
[13]. When treating TMD, its diagnosis and future treat-
ment plans should be approached from various perspec-
tives because of possible multifactorial nature of the
disorder. It is known that TMD patients recurrently
report tenderness in the masticatory musculature re-
gions such as in the temporalis and masseter muscles.
There are reports on the clinical use of BTX-A to relieve
the tenderness and restore functions of the TMJ. In one
report, some patients who were treated with BTX-A had
benefited from relief of myofascial pain [14].
BTX-A could also provide a control of parafunctional
oral habits that involve the masticatory muscles. BTX-A
is considered relatively safe since it does not cross the
blood-brain barrier with its effects localized in the per-
ipheral sensory nerves [15]. Binder et al. had reported
that even chronic headaches were completely or partially
improved on the patients who regularly received BTX-A
treatments in facial areas [16, 17].
Moreover, psychosocial factors should not be ignored in
diagnosing TMD since these factors sometimes influence
one’s physical status [18–21]. Myofascial pains quite often
come from psychological factors, and patients who suffer
from this etiological pain had shown high chronic pain-
related disability and depression/somatization scores [21].
Many studies support that BTX-A effectively diminishes
the muscle activity by inhibiting triggers of excessive mus-
cular contractions. In comparison between pre- and post-
treatment results of this study, graded pain score, charac-
teristic pain intensity, disability points, chronic pain grade,
and grade of nonspecific physical symptoms showed
statistically significant differences after the BTX-A injec-
tion therapy (p < 0.05). However, depression index did not
show significant changes. This insists that though states of
depression were not affected considerably by the injection
therapy, it had positive effects on somatization (with or
without pain items) and jaw disability of the TMD pa-
tients. Some studies suggest that parafunctional oral habits
could be the potential risk factors for myofascial pain and
disc derangement [22]. A high prevalence of parafunc-
tional oral habits (85.7 %) in our TMD patients is in ac-
cordance with findings of other studies. As changes in
graded pain scores before and after the treatment show,
BTX-A injections have improved disability levels in almost
all TMD subgroups (I, 4; III, 5; IV, 8; V, 4). This result
suggests that the BTX-A, which has a direct effect of
diminishing muscle contractions, may have therapeutic
gains even on complex and idiopathic TMD that involves
more than the muscular components of the TMJ.
Conclusions
Even with the positive outcomes shown from the study,
there are needs for more studies performed on a larger
sample size, with longer follow-up periods, in order to
scrutinize and evaluate the full effects of BTX-A injections.
Nevertheless, within the limitation of our study, clinical
injection of BTX-A in masticatory musculatures of TMD
patients can be considered as a useful supportive treatment
option for controlling complex TMD and helping its associ-
ated symptoms.
Competing interests
The authors declare that they have no competing interests.
Table 4 Graded pain score (GPS)
Degree Group Pre-treatment (n) Post-treatment (n)
No disability Grade 0 2 2
Low disability Grade I 3 6
Grade II 2 1
High disability Grade III 5 10
Grade IV 9 2
Total 21 21
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